St. Jude Children's Research Hospital
Developing genome editing technologies as safe and effective therapies for human genetic conditions such as sickle cell disease.
In the Tsai lab, our long-term goal is to advance safe and effective genome editing technologies to treat hematological conditions from bench to the bedside. Our current projects include:
Protein engineering of CRISPR-Cas genome editors with improved activity, specificity, and precise control of DNA repair outcomes.
Understanding safety of genome editors, including defining their genome-wide activities and interpreting the biological consequences.
Advancing autologous genome edited hematopoietic stem cells for treatment of patients with sickle cell disease to a clinical trial at St. Jude.
We are grateful for support from the NIH Common Fund Somatic Cell Genome Editing Consortium, the Doris Duke Charitable Foundation, and St. Jude/ALSAC.
Shengdar promoted to Associate Member.
Rachael starts in the lab as a lead researcher.
Elizabeth starts in the lab as a researcher.
Andrea awarded NIH F31 pre-doctoral fellowship.
Tsai and Weiss labs awarded renewal of DDCF funded grant to advance SCD genome editing therapy.
Abby joins the lab as a research technologist.
Shengdar honored by 2020 American Society of Gene and Cell Therapy Outstanding New Investigator Award.
Kasey awarded Diggs postdoctoral fellowship
Michelle, Kiera, and Tiffany join the lab as research technologists.
Andrea joins the lab as a graduate student.
Kasey joins the lab as a post-doctoral fellow.
Varun joins the lab as a senior research technologist.
Tsai lab and co-investigators awarded NIH Somatic Cell Genome Editing grant to develop a novel T-cell platform to understand biological adverse effects of genome editing.
Nick joins the lab as a staff scientist.